Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alnylam Pharmaceuticals Inc Receives Additional Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3


Tuesday, 20 Aug 2013 08:00am EDT 

Alnylam Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to ALN-AT3 as a therapeutic for the treatment of hemophilia A. As reported last week, the FDA has also granted ODD to ALN-AT3 for the treatment of hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), for the treatment of hemophilia - including hemophilia A, hemophilia B, and hemophilia A or B with 'inhibitors' - and other Rare Bleeding Disorders (RBD). 

Company Quote

90.99
2.23 +2.51%
12:59pm EDT